332 related articles for article (PubMed ID: 24953791)
21. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
Shona O; Gupta B; Vemala R; Sivaprasad S
Clin Exp Ophthalmol; 2011 Jan; 39(1):5-8. PubMed ID: 21040311
[TBL] [Abstract][Full Text] [Related]
22. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
23. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
24. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab.
Almony A; Mansouri A; Shah GK; Blinder KJ
Can J Ophthalmol; 2011 Apr; 46(2):182-5. PubMed ID: 21708088
[TBL] [Abstract][Full Text] [Related]
27. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12.
Williams TA; Blyth CP
Eye (Lond); 2011 Dec; 25(12):1617-21. PubMed ID: 21921947
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular Degeneration.
Blodi BA; Domalpally A; Corkery E; Osborne A; Blotner S; Grzeschik SM; Gune S
Ophthalmol Retina; 2023 Aug; 7(8):661-671. PubMed ID: 37086257
[TBL] [Abstract][Full Text] [Related]
29. Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab.
Grenga PL; Fragiotta S; Meduri A; Lupo S; Marenco M; Vingolo EM
Can J Ophthalmol; 2013 Oct; 48(5):394-9. PubMed ID: 24093186
[TBL] [Abstract][Full Text] [Related]
30. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.
Rayess N; Houston SK; Gupta OP; Ho AC; Regillo CD
Am J Ophthalmol; 2015 Jan; 159(1):3-8.e1. PubMed ID: 25217859
[TBL] [Abstract][Full Text] [Related]
32. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
33. Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration.
Shin HJ; Chung H; Kim HC
Retina; 2013 May; 33(5):964-70. PubMed ID: 23348865
[TBL] [Abstract][Full Text] [Related]
34. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
35. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
[TBL] [Abstract][Full Text] [Related]
36. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
37. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
Ramakrishnan MS; Yu Y; VanderBeek BL
JAMA Ophthalmol; 2020 Mar; 138(3):237-242. PubMed ID: 32027349
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review.
Bandukwala T; Muni RH; Schwartz C; Eng KT; Kertes PJ
Can J Ophthalmol; 2010 Dec; 45(6):590-5. PubMed ID: 21135894
[TBL] [Abstract][Full Text] [Related]
39. Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan.
Chang YS; Lee WJ; Lim CC; Wang SH; Hsu SM; Chen YC; Cheng CY; Teng YT; Huang YH; Lai CC; Tseng SH
Sci Rep; 2018 May; 8(1):7486. PubMed ID: 29748599
[TBL] [Abstract][Full Text] [Related]
40. Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab.
Gillies MC; Campain A; Walton R; Simpson JM; Arnold JJ; Guymer RH; McAllister IL; Hunyor AP; Essex RW; Morlet N; Barthelmes D;
Ophthalmology; 2015 Mar; 122(3):589-594.e1. PubMed ID: 25458197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
